Local Clinical Trials for Cancer Patients
Researchers at UCLA’s Jonsson Cancer Center have just launched several large studies of treatments for advanced breast and colorectal cancers that attempt to starve tumors by cutting off the blood supply they need to grow and flourish (by way of angiogenesis inhibitors).
The studies are open at UCLA’s Westwood campus and at more than 60 affiliated cancer network oncology offices throughout California and in Nevada and Montana.
Hundreds of patients are being sought to take part in three clinical trials to study the experimental anti-VEGF antibody (Avastin) in combination with chemotherapy on advanced breast and colorectal cancers. Researchers hope that by stopping or cutting off the formation of a new blood supply, they can starve and, hopefully, kill the cancer. (In these UCLA studies, an experimental antibody is teamed up with different chemotherapy drugs.)
Researchers believe the antibody will help the chemotherapy work more effectively, and vice-versa , providing a synergistic effect.
Dr. Fairooz Kabbinavar, a UCLA Jonsson Cancer Center scientist and physician who has studied the anti-VEGF antibody in the lab and in patients for the last nine years, heads up the three new clinical trials. Based on what he’s observed in the lab and in early patient studies, he is optimistic about the effectiveness of the anti-VEGF antibody. In addition to the Jonsson Cancer Center on UCLA’s Westwood campus, the antibody is available to patients in California community-based UCLA research network oncology offices in Bakersfield, Fresno, Fullerton, Inglewood, La Jolla, Lancaster, Long Beach, Monterey, Monterey Park, Northridge, Oxnard, Pasadena, Pomona, Rancho Mirage, Redondo Beach, Santa Barbara, Santa Cruz, Santa Maria, Santa Monica, Thousand Oaks, Valencia (at the UCLA Cancer Center, SCV) and Vista.
• For more information on the three studies, patients should call UCLA’s toll-free clinical trial hotline at (888) 798-0719 or Yvonne Chapman, R.N., research coordinator at the UCLA Cancer Center, SCV at 255-5350 .
• Clinical Trial for Ovulation Induction
If you are a woman between 18 and 39 who has absent or prolonged menstrual cycles and is having difficulty getting pregnant, you may be eligible for an approved clinical research study being conducted through the Center for Reproductive Health and Gynecology. Located in Valencia, the Center for Reproductive Health and Gynecology, provides patients with comprehensive fertility treatments, including treatment of hormonal disorders, ovulation induction, infertility surgery, male infertility and assisted reproductive technologies (ART).
If you qualify to be a part of this study, you will receive fertility treatment and associated medical care at no expense to you.
• For more information regarding the study/eligibility, contact Nicole Stinson, study coordinator at the Center for Reproductive Health and Gynecology at 254-0545 .
*
Female Smoking Epidemic
According to a recent report from the U.S. surgeon general, women now account for about 40 percent of all smoking-related deaths each year in the United States. In spite of the well-known dangers of smoking, 22 percent of U.S. women continue to light up.
Per “Women and Smoking: A Report of the Surgeon General,” presented at a March news conference by U.S. Surgeon General David Satcher, MD, Ph.D.,there has been a 600 percent increase in women’s death rates for lung cancer since 1950.
The leading cause of cancer deaths among women, lung cancer is primarily caused by cigarette smoking. The report’s findings included the following:
• Thirty percent of high school senior girls have smoked in the past month.
• Seventy-five percent of women who smoke want to quit smoking, but only about two percent are successful.
• More than 90 percent of lung cancer cases among U.S. women are due to smoking.
• Many women quit smoking while pregnant, but only one-third are still not smoking one year later.
• Smoking is higher among women who have only nine to 11 years of education, at 33 percent, than among women with 16 or more years of education, at 11 percent.
• Exposure to environmental tobacco smoke is a cause of lung cancer and coronary heart disease among women who are lifetime nonsmokers.
This new report also documented the millions of dollars the tobacco industry shells out on marketing smoking as the glamorous “norm” among powerful and intelligent women— while in reality, nearly 80 percent of U.S. adult women choose not to smoke. Key solutions to prevent and reduce smoking among women include: encouraging women of all ages to quit, implementing science-based cessation interventions, enacting statewide tobacco control programs and encouraging a more vocal constituency on the issue.
Women (and men), listen up— Kick the habit! Don’t let a burning roll of tobacco dictate your life expectancy.
• For more information on how to quit smoking contact your doctor or the American Cancer Society, SCV Unit at 298-0886
• Easing into Menopause
“Easing into Menopause— How to Make it Better,” a lecture on achieving physical and emotional well-being throughout peri-menopause and menopause will take place at 10 a.m. on Saturday at the Santa Clarita Family YMCA, 26147 McBean Pkwy. in Valencia.
Speaker Rose Drye, R.N., M.S.N. will discuss ways to go through this natural stage of life.
Call for reservations 253-3593 .
